Safety & Efficacy of 68Ga-DOTA-tyr3-Octreotide PET/CT in Diagnosis, Staging & Measurement of Response to Treatment in Patients With Somatostatin Receptor Positive Tumors: Comparison to Octreoscan Plus High-Resolution, Contrast Enhanced CT.

Trial Profile

Safety & Efficacy of 68Ga-DOTA-tyr3-Octreotide PET/CT in Diagnosis, Staging & Measurement of Response to Treatment in Patients With Somatostatin Receptor Positive Tumors: Comparison to Octreoscan Plus High-Resolution, Contrast Enhanced CT.

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 04 May 2017

At a glance

  • Drugs Gallium 68-DOTATOC (Primary) ; Indium-111-pentetreotide
  • Indications Medulloblastoma; Neuroblastoma; Neuroendocrine tumours; Phaeochromocytoma
  • Focus Diagnostic use
  • Most Recent Events

    • 30 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2017.
    • 20 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 07 May 2015 Planned primary completion date changed from 1 Mar 2014 to 1 Mar 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top